Imagion Biosystems

Imagion Biosystems Gross Margin

The Gross Margin of Imagion Biosystems (IBX.AX) as of Oct 29, 2026 is -27.21 %. In the previous year, Gross Margin was 84.95 % — a change of -132.03% (lower).

Gross Margin

-27.21 %

YoY

-132.03%

Last updated:

Gross Margin of Imagion Biosystems is 2025 -27.21 % . Gross Margin of Imagion Biosystems was 2024 84.95 % . It decreases by -132.03% lower compared to the previous year.

For Imagion Biosystems, the gross margin of -27.2% is up versus -1,061.2% a few years ago.

The Imagion Biosystems Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
-1,621.19 AUD
Jan 1, 2019
-452.27 AUD
Jan 1, 2020
-1,290.63 AUD
Jan 1, 2021
-1,061.20 AUD
Jan 1, 2022
-663.76 AUD
Jan 1, 2023
-25.84 AUD
Jan 1, 2024
84.95 AUD
Jan 1, 2025
-27.21 AUD
The Imagion Biosystems Gross Margin history
YEARGross MarginYoY
-27.21 %-132.03%
84.95 %-428.76%
-25.84 %-96.11%
-663.76 %-37.45%
-1,061.20 %-17.78%
-1,290.63 %+185.37%
-452.27 %-72.10%
-1,621.19 %-1,721.19%
100.00 %-100.06%
-180,250.00 %-180,350.00%
100.00 %0.00%
100.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imagion Biosystems Stock analysis

What does Imagion Biosystems do? Imagion Biosystems Ltd develops non-radioactive diagnostic imaging technology through its MagSense and PrecisionMRX product lines. MagSense uses cancer-specific magnetic nanoparticles for detecting breast, prostate, and ovarian cancers, with a Phase I clinical study ongoing for its HER2 imaging agent. PrecisionMRX offers coated nanoparticles including Dextran-Coated, mPEG Coated, Oleic Acid Coated, and Carboxylic Acid Functionalized variants for magnetic relaxometry applications. The company generates revenue primarily through research and development activities, focusing on advanced cancer diagnostics and medical imaging solutions. The firm operates exclusively in the Research and Development segment, targeting medical professionals and healthcare institutions requiring innovative diagnostic tools. MagSense technology is designed as an injectable solution tailored to specific cancer types, while PrecisionMRX nanoparticles serve biomedical applications demanding high precision. These products are developed for use in cancer diagnostics, with clinical studies validating their effectiveness in detecting critical diseases. Imagion Biosystems' revenue streams derive from the development and commercialization of its proprietary imaging technologies. The company's MagSense platform enables functional imaging for cancer detection without radioactive materials, appealing to healthcare providers seeking safer diagnostic alternatives. PrecisionMRX nanoparticles support specialized biomedical applications, offering customizable solutions for medical imaging needs across various cancer types. Imagion Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imagion Biosystems stock

Gross Margin of Imagion Biosystems is -27.21 % in 2025.

Gross Margin of Imagion Biosystems changed from 84.95 % to -27.21 %, representing a -132.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Imagion Biosystems since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Imagion Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Imagion Biosystems

All Key Metrics — Imagion Biosystems